Answers are grounded in this paper and cite their sources.
Methodological challenges in defining aspirin and clopidogrel resistance highlight the poor correlation among current platelet function tests and suggest platelet size measurement as a potential alternative.
Antiplatelet drug resistance is one of the urgent issues in current cardiovascular medicine. Many platelet function tests have been used to define responsiveness of patients with cardiovascular disease to aspirin and clopidogrel. In most studies, cut-off values of platelet function tests for defining responsiveness to antiplatelets were chosen arbitrarily. Different tests provided wide-ranging figures of the prevalence of aspirin and clopidogrel resistance, suggesting poor correlation between currently available platelet function tests. Measurement of platelet size seems to be a promising approach for monitoring antiplatelet drug therapy. This commentary highlights some limitations of studies on aspirin and clopidogrel resistance in patients undergoing coronary interventions.
No takes yet. Share an insight, caveat, or question.
Armen Yuri Gasparyan (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: